Rethinking Hyperkalemia to Optimise RASSi Therapy26 January 2022
Hyperkalemia is a frequent and recurrent event in patients with heart failure, chronic kidney disease and diabetes, especially in those with multiple comorbidities and/or treated with RASSi therapy. Hyperkalemia is associated with worse patient outcomes. Treatment guidelines recommend RASSi therapy to improve patient outcomes. However, they often also recommend decreasing or discontinuing RASSi therapy in the presence of hyperkalemia. Re-challenging with RASSi therapy does not consistently occur following reduction or discontinuation. Recent heart failure consensus statements and diabetic management in chronic kidney disease guidelines recommend managing hyperkalemia, including the use of novel potassium binder, so patients can remain on RASSi therapy.
After the lecture, the participants will be able to gain an understanding on:
Click here for more lecture details.
To register, scan the QR code or click on the web link. Registration closes on 31 December 2021, Friday.
Upon registration, participants agreed to PGAHI Terms & Conditions. Kindly note that PGAHI reserves the right of final decision on lecture registration.
26 January 2022, Wednesday
6.30 pm - 7.30 pm
Zoom Cloud Meetings
Registration Closing Date:
31 December 2021, Friday
(Zoom Capacity: 500
This lecture will be conducted via Zoom Cloud Meetings app. For ease of accessing the lecture, please download/update Zoom Cloud Meetings app. Details of the lecture meeting link will be sent to the successful registrants nearer the lecture date.)